Clinical trial

Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)

NCT01788332

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2014-01-01

PhasePHASE2

Study timeline

Study start (actual)2014-01-01Date precision: month

Registry last updated2018-10-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Interventions

OlaparibDRUG · verified · RxNorm: olaparib

PlaceboOTHER

Sponsors & collaborators

Lisette Nixonlead sponsor

AstraZenecacollaborator

Mapped research locations

LondonUnited Kingdom1 ManchesterUnited Kingdom1 GlasgowUnited Kingdom1 SheffieldUnited Kingdom1 LeicesterUnited Kingdom1 LeedsUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01788332 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.